CUPIDGUT - Project
Parkinson’s disease (PD) is a rapidly growing neurodegenerative disorder affecting up to 2–3% of people over 65. It is caused by dopaminergic neuron loss in the substantia nigra, leading to motor symptoms like tremors, rigidity, and bradykinesia. Current treatments only manage symptoms, mainly through dopamine replacement (e.g., levodopa). Growing evidence links gut microbiome alterations to PD, as gastrointestinal dysfunction often precedes motor symptoms. Microbial activity also affects levodopa metabolism, influencing treatment efficacy.
This project builds on groundbreaking fecal microbiota transplantation (FMT) trials. The GUTPARFECT study showed that PD patients receiving healthy donor FMT experienced motor symptom improvements, particularly between 6 and 12 months post-treatment, along with better gastrointestinal function. The ongoing FMT4PD trial is further assessing motor and microbiome changes, with both studies confirming FMT’s safety.
The CUPIDGUT project aims to refine these findings by analyzing trial data and optimizing a multicenter FMT study. Key goals include identifying factors influencing FMT success, refining procedures, and ensuring safety. Scientists and clinicians will explore patient and donor stratification and potential biomarkers to improve treatment outcomes.
Ultimately, the consortium seeks to establish FMT as a viable PD therapy by developing clinical guidelines for widespread adoption. This research has the potential to revolutionize PD treatment, offering a novel approach to disease management beyond symptom control.